<DOC>
	<DOCNO>NCT02234583</DOCNO>
	<brief_summary>This open-label study DS-5565 subject either complete participation precede Phase 3 study DS-5565 fibromyalgia ( FM ) ; i.e . DS5565-A-E309 , DS5565-A-E310 , DS5565-A-E311 de novo subject . Eligible subject assign receive open-label DS-5565 52 week . All subject receive DS-5565 15 mg daily ( QD ) first three week treatment period . After three week , subject may titrate 15 mg twice daily ( BID ) base protocol-specified criterion .</brief_summary>
	<brief_title>An Open-Label Extension Study DS-5565 52 Weeks Pain Associated With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Able give write informed consent Completed participation ( i.e . complete EndofTapering visit ) precede study DS 5565 FM ( DS5565AE309 , DS5565AE310 , DS5565AE311 ) Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy study 4 week study completion Able complete subjectreported questionaires per investigator 's judgement The subject must experience significant safety issue precede study , investigator 's judgment , would adversely impact subject 's wellbeing longterm extension De Novo Subjects Age ≥ 18 year Able give write informed consent Able complete subjectreported questionnaire per investigator 's judgment At screening , subject must meet 1990 American College Rheumatology ( ACR ) criterion FM , i.e . widespread pain present least 3 month pain least 11 18 specific tender point site . In addition , 2010 ACR criterion must meet : Widespread pain index ( WPI ) ≥ 7 symptom severity ( SS ) scale score ≥ 5 , WPI 3 6 SS scale score ≥ 9 Symptoms present similar level least 3 month The subject disorder would otherwise explain pain ADPS ≥ 4 11point numeric rating scale ( NRS ) past 7 day prior first dose ( base completion least 4 daily pain diary 7day baseline period ) Subject must document evidence fundoscopic examination ( pupil dilation ) within 12 month prior screen screen Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy study 4 week study completion Clinically significant unstable neurologic , psychiatric , ophthalmologic , hepatobiliary , respiratory , hematologic illness unstable cardiovascular disease ( e.g . severe hypotension , uncontrolled cardiac arrhythmia , myocardial infarction ) concurrent disease precede study ( rollover subject ) within 12 month prior screen ( de novo subject ) opinion investigator would interfere study participation assessment safety tolerability Subjects risk suicide define response CSSRS opinion investigator . Subjects severe uncontrolled depression , judgment investigator , make subject inappropriate entry study Subjects pain due condition ( e.g . DPNP postherpetic neuralgia ) , opinion investigator , would confound assessment selfevaluation pain associate FM Subjects pain due widespread inflammatory musculoskeletal disorder ( e.g . rheumatoid arthritis , lupus ) widespread rheumatic disease FM . Abuse dependence prescription medication , street drug , alcohol within last 1 year A diagnosis untreated sleep apnea initiation treatment sleep apnea within past 3 month Known hypersensitivity α2δ ligands component study medication Pregnancy breastfeeding , intent become pregnant study period Abnormal investigative test ( i.e . ECGs ) laboratory value judge investigator clinically significant EndofTreatment visit ( Visit Week 13 ) preceding study ( rollover subject ) screening ( de novo subject ) , particular focus : For De Novo Subjects Only Unable undergo prestudy washout prohibit concomitant medication ( list Section 5.2.1 protocol ) Current severe uncontrolled major depressive disorder anxiety disorder assess Miniinternational Neuropsychiatric Interview ( MINI ) interview ( Version 6.0 ) screening exclude , mild moderate major depression anxiety disorder permit provided investigator assess patient clinically stable appropriate entry study Any diagnosis lifetime bipolar disorder psychotic disorder Subject currently enrol yet complete least 30 day since end another investigational device drug study receive investigational agent Subject employee study center , immediate family member* employee study center , employee Daiichi Sankyo , INC Research , study vendor support study . * ( spouse , parent , child , sibling , whether biological legally adopt )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>fibromyalgia</keyword>
</DOC>